Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 (IRAK1) Pathway Activation (PAIR)

NCT04520269 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT04520269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04520269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 (IRAK1) Pathway Activation (PAIR)
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 13, 2020
Completion date
July 31, 2026
Enrollment
74 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer